STOCK TITAN

Semnur Pharms (SMNR) 424B Filings

SMNR OTC

Here are the 424B prospectus supplements from Semnur Pharms Inc (SMNR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow SMNR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMNR filings page.

Rhea-AI Summary

Semnur Pharmaceuticals, Inc. is registering the resale of up to 203,737,349 shares of its Common Stock and the issuance of up to 7,432,122 shares upon the exercise of up to 510,000 warrants. The prospectus supplement updates the Form S-1 and states the company will not receive proceeds from the resale of those Resale Shares but will receive proceeds from any warrant exercises.

The company also disclosed a binding term sheet with iHolding Group LLP for a proposed $100,000,000 investment at $10.00 per share (approximately 10,000,000 shares), subject to due diligence, board and stockholder approvals, definitive agreements and customary closing conditions. The supplement notes last reported trading prices of Common Stock at $0.78 per share and Public Warrants at $0.04 per warrant on July 6, 2026.

Rhea-AI Summary

Semnur Pharmaceuticals, Inc. registers up to 203,737,349 shares of Common Stock for resale and up to 7,432,122 shares of Common Stock issuable upon exercise of warrants, and registers up to 510,000 warrants.

This prospectus supplement updates the Form S-1 prospectus and attaches a Form 8-K. The filing states the company will not receive proceeds from resale by selling holders, but will receive proceeds from any warrant exercises. The supplement lists sponsor, Scilex, Biconomy and other selling holders and includes voting and meeting results disclosed in the attached Form 8-K.